Pharma companies at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

11 pharma companies are at EBF 2026 — 29 presentations on the program. Most represented: Roche (9 on the program), Sanofi (5 on the program), GSK (4 on the program). 6 of them have their own page in this guide. As of Oct 13, 2026.

All 63 organizations at EBF 2026 →

Showing 1–11 of 11 organizations

Organization	EBF 2026 Attendance
Roche Basel, Switzerland
roche.com Pharma Pharmaceutical and diagnostics group developing medicines in oncology, immunology, neuroscience and ophthalmology, alongside its Roche Diagnostics business.	Talk Tue Nov 17 11:30–11:50am Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence Clinical Speed meets GLP Rigor: Upgrading an IVD Immunoanalyzer for High-Throughput PK/PD Analysis in a Bioanalytical Laboratory - Lessons Learnt Automation & AI · Ligand binding Talk Tue Nov 17 2:40–3pm Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics LC-MS Bioanalysis of Lipid Conjugated siRNAs: Analytical Challenges and Novel Approaches New modalities · LC–MS Talk Tue Nov 17 5:20–5:40pm Part of Session 7: BM CoU in practice Navigating Soluble Biomarker Complexity: Challenges, Assay Strategy, and Case Studies Biomarkers Talk Wed Nov 18 9–9:20am Part of Session 10: Bioanalysis Beyond Conventional Matrices From First-in-Human to Multi-Site Trials: Practical Bioanalytical Strategies to Preserve CSF Pharmacokinetic Data for Highly Adsorptive Molecules Sampling Talk Wed Nov 18 9:20–9:40am Part of Session 12: Assay life cycle Assay Lifecycle in Practice: Strategic Stewardship, Change Control, and Revalidation Case Studies Regulation Talk Wed Nov 18 9:40–10am Part of Session 10: Bioanalysis Beyond Conventional Matrices Operationalizing Unstable Biomarkers: How Biosample Operations and Bioanalysis Enable Successful Scale-Up from Single-Site to Multi-Site Clinical Trials Biomarkers · Sampling Talk Wed Nov 18 5–5:20pm Part of Workshop 10: ADA - Adaptive Tier Overcoming the 3-Tier ADA Testing Paradigm via Mechanistic Assay Understanding Immunogenicity Talk Thu Nov 19 9:20–9:40am Part of Session 16: Protein MS tech 1 A Multiplexed LC-MS/MS Strategy for the Simultaneous Quantification of a Transgene Protein and its Endogenous Counterpart in a Gene Therapy Program. LC–MS Talk Thu Nov 19 11:30–11:50am Part of Session 20: Pushing the Limits of Sensitivity and Multiplexing in Bioanalysis Navigating High-Plex Profiling and Targeted Quantification in Drug Development Biomarkers
Sanofi Paris, France
sanofi.com Pharma Pharmaceutical company developing medicines and vaccines in immunology, rare diseases, neurology and oncology.	Talk Wed Nov 18 12:10–12:30pm Part of Workshop 2: Emerging challenges in the e-environment Rethinking the Discovery Bioanalytical Dataflow using a Bespoke End-to-End Digital Solution Automation & AI Talk Wed Nov 18 12:20–12:40pm Part of Session 14: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 2 The Immunogenicity Nexus: Investigating the Predictive Relationship Between Early-Onset ADA Kinetics in NHP and Human Immune Responses Immunogenicity Talk Thu Nov 19 9–9:20am Part of Session 15: Flow From Raw Data to Insights in Minutes: Development of an Automated Flow Cytometry Data Pipeline for Preclinical Studies Cell-based · Automation & AI Talk Thu Nov 19 2–2:20pm Part of Session 21: Protein MS Tech 2 Generic Hybrid Immunocapture LC-MS/MS Approach for Integrity Assessment of Multispecific Antibodies in Clinical Studies: A Breakthrough Bioanalytical Strategy LC–MS · New modalities Talk Thu Nov 19 2:20–2:40pm Part of Session 21: Protein MS Tech 2 Advanced LC-MS Strategies for In Vivo Bioanalysis of Next-Generation Biotherapeutics: From Method Development to Multi-Therapeutic Area Applications LC–MS · New modalities
GSK London, UK
gsk.com Pharma Pharmaceutical company developing vaccines and medicines for infectious diseases, HIV, respiratory and immune-mediated diseases, and oncology.	Talk Tue Nov 17 12:10–12:30pm Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence Automation Innovations Drive Efficiencies in Flow Cytometry Clinical Sample Testing Automation & AI · Cell-based Talk Tue Nov 17 4:40–5pm Part of Session 8: Pharma CRO Lessons Learned During In-Licensing Talk Wed Nov 18 11:20–11:40am Part of Session 13: BioA Clinic It’s not your assay, it’s us: reappraising the CoU in response to extra-analytical factors Biomarkers Talk Thu Nov 19 9:40–10am Part of Session 15: Flow Operationalising high-parameter flow cytometry for large-scale clinical research Cell-based
AstraZeneca Cambridge, UK
astrazeneca.com Pharma Pharmaceutical company with medicines in oncology, cardiovascular, renal and metabolic, respiratory and immunology, and rare diseases.	Talk Wed Nov 18 4:35–4:50pm Part of Workshop 7: New Approach Methodologies - NAM Bioanalysis as a Scientific Partner in NAM Development: Advancing a Bone Marrow Microphysiological System from Characterisation to Translational Implementation Sampling Talk Thu Nov 19 11:30–11:50am Part of Session 18: Connecting Metabolism, Exposure and Multi-Omics From Tissue Microenvironments to Mechanism: Deploying LMD-Omics Across Drug Exposure, Toxicity and Disease Biology LC–MS
Merck KGaA Darmstadt, Germany
merckgroup.com Pharma Science and technology group whose healthcare business develops medicines in oncology, neurology and fertility, alongside life science and electronics businesses.	Talk Wed Nov 18 10:20–10:40am Part of Session 11: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 1 Never Too Old to Be Questioned: What a 20-Year-Old Product Taught Us About Immunogenicity Expectations Immunogenicity Talk Thu Nov 19 11:50am–12:10pm Part of Session 19: ADC Bioanalysis, From Community Recommendations to Complex PK Decisions Hybrid Immunocapture (IC)/LC-MS methods for the simultaneous quantification of Total Antibody and Conjugated Payload across different species case studies. New modalities · LC–MS
UCB Brussels, Belgium
ucb.com Pharma Biopharmaceutical company developing medicines for immunology and neurology, including epilepsy and inflammatory diseases.	Talk Tue Nov 17 3–3:20pm Part of Session 4: Advancing the 3Rs: Smarter Sampling, Surrogate Matrices and Leaner Workflows Routine use of surrogate matrix in regulated bioanalysis Sampling Talk Tue Nov 17 5–5:20pm Part of Session 9: New technologies and emerging modalities in Bioanalysis: PCR Overcoming tissue matrix interference in a droplet digital PCR analytical method for biodistribution assessment PCR
Fresenius Kabi SwissBioSim Eysins, Switzerland
fresenius-kabi.com Pharma Fresenius Kabi's biosimilars development unit.	Talk Tue Nov 17 3–3:20pm Part of Session 6: Biosimilars Root cause analysis of unexpected Denosumab Pharmacokinetic profile fluctuations in Study FKS518-001 Ligand binding
Genentech South San Francisco, California
gene.com Pharma Member of the Roche Group that discovers, develops and markets medicines for cancer, immunology and neuroscience.	Talk Tue Nov 17 6–6:20pm Part of Session 7: BM CoU in practice Establishing a Sustainable Analytical Strategy for Translational Kidney Safety Biomarkers Biomarkers
Johnson & Johnson Innovative Medicine
jnj.com Pharma Johnson & Johnson's pharmaceutical business, formerly Janssen.	Talk Tue Nov 17 4:40–5pm Part of Session 9: New technologies and emerging modalities in Bioanalysis: PCR Automating qPCR Workflow: Investigation and Resolution of Over-Recovery from Low-Copy Numbers During Workflow Development PCR · Automation & AI
Novartis Basel, Switzerland
novartis.com Pharma Pharmaceutical company developing medicines in cardiovascular, immunology, neuroscience and oncology, including cell, gene and radioligand therapies.	Talk Tue Nov 17 5:20–5:40pm Part of Session 8: Pharma CRO Beyond the Pilot: Scaling a Centralized Sponsor Interface Model Across Strategic CRO Partnerships
Novo Nordisk Bagsværd, Denmark
novonordisk.com Pharma Pharmaceutical company focused on diabetes, obesity and rare blood and endocrine diseases, including GLP-1 medicines.	Talk Tue Nov 17 2–2:20pm Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics Beyond Plasma PK: Fit-for-Purpose Bioanalysis for Next-Generation siRNA and ASO Therapeutics New modalities · LC–MS